Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support.
Aged
COVID-19
/ complications
Comorbidity
Female
Heart Failure
/ epidemiology
Heart Ventricles
Heart-Assist Devices
/ statistics & numerical data
Hospitalization
/ statistics & numerical data
Humans
Male
Middle Aged
Pandemics
Registries
SARS-CoV-2
/ isolation & purification
United States
/ epidemiology
COVID-19
SARS-CoV-2
heart failure
hospitalization
outcomes research
ventricular assist device
Journal
Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
pubmed:
6
4
2021
medline:
28
4
2021
entrez:
5
4
2021
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic continues to afflict millions of people worldwide. Patients with end-stage heart failure and left ventricular assist devices (LVADs) may be at risk for severe COVID-19 given a high prevalence of complex comorbidities and functional impaired immunity. The objective of this study is to describe the clinical characteristics and outcomes of COVID-19 in patients with end-stage heart failure and durable LVADs. The Trans-CoV-VAD registry is a multi-center registry of LVAD and cardiac transplant patients in the United States with confirmed COVID-19. Patient characteristics, exposure history, presentation, laboratory data, course, and clinical outcomes were collected by participating institutions and reviewed by a central data repository. This report represents the participation of the first 9 centers to report LVAD data into the registry. A total of 40 patients were included in this cohort. The median age was 56 years (interquartile range, 46-68), 14 (35%) were women, and 21 (52%) were Black. Among the most common presenting symptoms were cough (41%), fever, and fatigue (both 38%). A total of 18% were asymptomatic at diagnosis. Only 43% of the patients reported either subjective or measured fever during the entire course of illness. Over half (60%) required hospitalization, and 8 patients (20%) died, often after lengthy hospitalizations. We present the largest case series of LVAD patients with COVID-19 to date. Understanding these characteristics is essential in an effort to improve the outcome of this complex patient population.
Sections du résumé
BACKGROUND
BACKGROUND
The coronavirus disease 2019 (COVID-19) pandemic continues to afflict millions of people worldwide. Patients with end-stage heart failure and left ventricular assist devices (LVADs) may be at risk for severe COVID-19 given a high prevalence of complex comorbidities and functional impaired immunity. The objective of this study is to describe the clinical characteristics and outcomes of COVID-19 in patients with end-stage heart failure and durable LVADs.
METHODS
METHODS
The Trans-CoV-VAD registry is a multi-center registry of LVAD and cardiac transplant patients in the United States with confirmed COVID-19. Patient characteristics, exposure history, presentation, laboratory data, course, and clinical outcomes were collected by participating institutions and reviewed by a central data repository. This report represents the participation of the first 9 centers to report LVAD data into the registry.
RESULTS
RESULTS
A total of 40 patients were included in this cohort. The median age was 56 years (interquartile range, 46-68), 14 (35%) were women, and 21 (52%) were Black. Among the most common presenting symptoms were cough (41%), fever, and fatigue (both 38%). A total of 18% were asymptomatic at diagnosis. Only 43% of the patients reported either subjective or measured fever during the entire course of illness. Over half (60%) required hospitalization, and 8 patients (20%) died, often after lengthy hospitalizations.
CONCLUSIONS
CONCLUSIONS
We present the largest case series of LVAD patients with COVID-19 to date. Understanding these characteristics is essential in an effort to improve the outcome of this complex patient population.
Identifiants
pubmed: 33813838
doi: 10.1161/CIRCHEARTFAILURE.120.007957
pmc: PMC8059761
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e007957Subventions
Organisme : NIA NIH HHS
ID : P30 AG059307
Pays : United States
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
JACC Case Rep. 2020 Jul 15;2(9):1315-1320
pubmed: 32292915
JACC Heart Fail. 2013 Feb;1(1):31-9
pubmed: 24621797
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Ann Thorac Surg. 2008 May;85(5):1656-61
pubmed: 18442560
Card Fail Rev. 2015 Apr;1(1):25-30
pubmed: 28785427
J Am Coll Cardiol. 2020 Jun 30;75(25):3177-3183
pubmed: 32380033
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765
pubmed: 32555134
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
MMWR Morb Mortal Wkly Rep. 2020 Jul 03;69(26):841-846
pubmed: 32614810
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nat Rev Nephrol. 2021 Jan;17(1):46-64
pubmed: 33077917
N Engl J Med. 2019 Apr 25;380(17):1618-1627
pubmed: 30883052
Ann Thorac Surg. 2019 Feb;107(2):341-353
pubmed: 30691584
J Card Fail. 2020 May;26(5):438-439
pubmed: 32305569
JACC Heart Fail. 2020 Aug;8(8):681-691
pubmed: 32493638
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079